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Abstract
Background: Cytoreductive surgery and hyperthermic in-
traperitoneal chemotherapy (CRS-HIPEC) is associated with 
considerable postoperative morbidity, including ileus and 
infectious complications. Perioperative care is believed to be 
an important factor for the development and treatment of 
postoperative morbidity. Patients and Methods: Data on 
case-matched patients from a retrospective database of 
2 Dutch HIPEC centres was compared. Patient selection and 
procedures were identical in both hospitals although peri-
operative management items differ slightly. In centre B, im-
mediate total parenteral nutrition (TPN), suprapubic urine 
bladder catheter placement (SPCs) and selective decontam-
ination of the digestive-tract are standard care for CRS-HIPEC 
patients, while in centre A, they are not. Results: From a total 
of 223 patients, 68 consecutive patients from centre B were 
compared to 68 matched patients from centre A. TPN was 
administered to 54.4% of patients in centre A because of pro-
longed ileus, whereas it was standard of care in centre B. In 
all, 105 (77.2%) patients experienced postoperative compli-
cations including 17.6% who had a grades III–IV complica-
tion. The incidence of grade III-V complications was 18 
(26.4%) in centre A and 8 (11.8%) in centre B (p = 0.03). Me-
dian hospital stay was 12 days (7–84) in A and 11(6–80) in 
centre B (p = 0.546). Conclusions: Gastrointestinal recovery 
after CRS-HIPEC seems to take longer as compared to other 
surgical procedures. Between the 2 centres, a significant dif-
ference in severe complications was found, while standard 
TPN, selective bowel decontamination and SPCs were the 
only identified differences in perioperative care.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
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Introduction
Globally, colorectal cancer is the third most com-
mon cancer in males and the second in females [1]. The 
advanced stage of disease is present in approximately 
20% of patients at first presentation [2], including 
4–7% presenting with synchronous peritoneal carcino-
matosis (PC) [3]. Patients with advanced T and N stage, 
poor tumour differentiation grade, mucinous tumours, 
younger age and right sided localization of the primary 
tumour have a higher risk for PC [3–5]. PC of colorec-
tal origin has always been associated with poor prog-
nosis and early studies in which patients were treated 
with palliative  chemotherapy, reported median surviv-
al ranging from 3.1 to 7.0 months [5, 6]. Later studies 
indicate that modern  chemotherapy regimens can in-
crease survival up to a median of 12.5 months [7]. 
Complete cytoreductive surgery (CRS) and hyperther-
mic intraperitoneal chemotherapy (HIPEC) have dem-
onstrated to significantly increase survival in selected 
patients with PC of colorectal origin [8–11]. Postop-
erative recovery in these patients is slower and associ-
ated with more morbidity compared to other abdomi-
nal procedures [12].
In elective colorectal surgery, fast track recovery pro-
grams that adhere to the ‘enhanced recovery after sur-
gery’ (ERAS) principles [13, 14], have been demonstrat-
ed to be safe and effective [15, 16]. ERAS programs in 
colorectal surgery cause faster recovery and fewer com-
plications [17, 18]. While patients operated for conven-
tional colorectal, liver or gastro-intestinal tumours do 
benefit from its effectiveness, the distinctive postopera-
tive course after CRS and HIPEC does not allow the ap-
plication of standard ERAS protocols. This is not sur-
prising, since the procedure is usually much longer and 
leads to extensive peritoneal trauma. Prolonged postop-
erative ileus (POI) frequently occurs after HIPEC. POI 
hinders patient recovery and increases postoperative 
morbidity, hospital costs, readmission rates and postop-
erative hospital stay (HS) [19–22]. Patients with PC of 
colorectal cancer treated with CRS and HIPEC in 2 cen-
tres between 2010 and 2015 were case-matched and ana-
lysed retrospectively. Both hospitals share identical pa-
tient selection standards and operative procedures in ac-
cordance with the nationwide protocol. The perioperative 
management however is different on 3 major items. 
These are the standard use of total parenteral nutrition 
(TPN), selective decontamination of the digestive tract 
(SDD) and suprapubic bladder catheters (SPCs) in one 
of the centres.
The aim of the current study was to gain insight into 
early gastrointestinal recovery and perioperative morbid-
ity in this specific group of patients and to evaluate the 
effect of 2 different perioperative care protocols on these 
outcomes.
Patients and Methods
Patients
Complete details on consecutive patients with PC of colorec-
tal origin treated with CRS and HIPEC in Radboudumc Nijme-
gen and Catharina Ziekenhuis Eindhoven between 2010 and 
2015 were available for this study. Exclusion criteria were non-
primary HIPEC procedures or other origins, for example, meso-
thelial origin. A total of 68 consecutive patients from Radbou-
dumc Nijmegen were included and compared with 68 best 
matching patients selected from the 155 consecutive patients 
available from Catharina Ziekenhuis Eindhoven. Relevant pa-
tient-, tumour-, recovery- and treatment (procedure)-related 
data were collected in a retrospective database. Matching vari-
ables were age at time of surgery, BMI, metachronous or syn-
chronous peritoneal carcinomatosis and peritoneal cancer index 
(PCI). After matching, a total of 136 patients were analysed. 
Data acquisition and analysis were approved by the local Ethics 
Committee.
HIPEC Centres
Both institutes involved in this study are Dutch HIPEC referral 
centres located in the southern region of The Netherlands. Indica-
tions for treatment with CRS and HIPEC and the applied opera-
tive techniques are identical and based on national consensus. 
Perioperative care protocols for these patients are identical in both 
hospitals except for 3 items: SDD, perioperative placement of su-
prapubic catheters and TPN started on the first day after opera-
tion are standard in centre B. In the other centre, Foley type ure-
thral catheters are the standard of care and TPN and SDD are not 
included in the standard care protocol. These differences provid-
ed the opportunity to evaluate gastrointestinal recovery and com-
plications as related to standard TPN plus SDD and suprapubic 
urine bladder catheters versus on-demand TPN, no SDD and 
transurethral catheters. 
Standard TPN Protocol
The nutritional needs of all patients in centre B were calculated 
on an individual patient level to provide adequate TPN. A dietician 
used the revised Harris and Benedict equation to calculate base 
caloric demand [23]. To reach adequate caloric intake for surgi-
cally treated patients, a surplus of 30–50% was added to the out-
come of the equation.
Antibiotic prophylaxis
Centre A administered an i.v. dose of 2,000 mg cefazolin 
and 500 mg metronidazole 30 min prior to incision; adequate 
dosing of profylaxis was continued for the duration of the 
 procedure. In centre B, the same dose of metronidazole was ad-
ministered 30 min prior to incision. On the day prior to the 
procedure, patients received an intravenous dose of 2,000 mg 
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Ceftriaxone at 10 pm Infectious complications that required ad-
ditional antibiotic treatment were treated according to local 
protocols.
SDD in Centre B
For SDD, additional to the prophylaxis mentioned above, 
1,000 mg Tobramycin/Colistin/Amphotericin-B oromucosal paste 
was applied 4 times per day, complemented by a 10-mL gastrointes-
tinal solution until oral food intake was resumed. SDD was used ac-
cording to local protocol and is considered a valuable addition of 
antibiotic treatment to reduce the risk of infections after colorectal 
surgery [24, 25].
Urine Catheters
In centre B, SPCs are routinely placed during the first stage of 
the CRS-HIPEC procedure. 
HIPEC and CRS
All procedures were performed by a specialized surgical team 
with ample experience in HIPEC. Leading HIPEC surgeons from 
both teams have crossed over to the other centre to participate 
in  CRS-HIPEC surgery. All surgeons were directly or indirect-
ly  trained by the Netherlands Cancer Institute surgical team 
and therefore adhere to identical surgical techniques and proce-
dures. Surgeons from both centres operated cases together in both 
hospitals. Peritoneal tumour extensiveness was scored using the 
PCI [26, 27].
Peritonectomy procedures were performed according to prin-
ciples previously described by Sugarbaker [26]. Standard total 
omentectomy was part of all cytoreduction procedures that were 
performed in both centres. The gastro-omental arcade, previously 
known gastro-epiploic arcade, is often part of the omental resec-
tion specimen. In several cases, the arcade was spared. 
The aim of each procedure was to achieve complete macro-
scopic resection, which was scored using the CC-score (CC0: 
complete macroscopic resection, CC1: residual tumour nodules 
< 2.5 mm, CC2: residual tumour nodules larger than 2.5 mm). All 
procedures were performed as open “coliseum” surgery. For 
HIPEC with Mitomycine C, a solution of 35 mg/m2 (maximum 
70 mg) in 0.9% NaCl was used to perfuse the abdomen at a tem-
perature of 42–43  ° C for 90 min. In patients perfused with oxali-
platin, systemic chemotherapy with leucovorin and 5-fluoro-
uracil (20 and 400 mg/m2) was administered prior to HIPEC. 
Oxaliplatin 460 mg/m2, in 5% dextrose 42–43  ° C was used for 30 
min perfusion of the peritoneal cavity at 42–43  ° C. During the 
historic period from 2010 to 2015 of the study, the treatment pro-
tocol was revised and changed from Mitomycine C to oxaliplatin 
in 2014, in accordance with the national protocol update. 
Postoperative Recovery
The date of the HIPEC procedure was defined as day 0. Mul-
tiple characteristics were registered as indicators of postoperative 
gastro-intestinal status: relief of nasogastric tube (used for gastric 
drainage), first day of tolerance of oral nutrition (not being clear 
fluids), first stool, start- and termination of TPN. Relief of naso-
gastric tube was defined as the day on which the tube was removed, 
provided no replacement in the following days during hospitaliza-
tion was necessary. Oral tolerance was considered to be present 
when a patient experienced no nausea or vomiting after oral intake 
other than water or transparent liquid. First stool was defined as 
the day of the first defecation or enterostomy production (other 
than the commonly observed serous or postoperative early pro-
duction on day 0–1). Termination of TPN was defined by the last 
day a patient received any amount of intravenous nutrition. 
Complications
Complications were scored using the Clavien Dindo complica-
tion classification [28]. Since TPN was part of the care protocol in 
centre B, TPN was excluded as complication criterium to score 
complications. 
Statistical Analyses
Statistical analyses were performed using the Statistical Pack-
age for Social Sciences, version 22.0 (IBM Corp., Armonk, NY, 
USA). Comparisons of means and medians, respectively, were 
conducted with Student t test or Mann-Whitney U test depending 
on distribution. Categorical variables were cross-tabulated and 
significance was determined by a chi-square test or Fisher’s exact 
test according to sample size.
Pearson correlation was used to identify correlated variables. 
Correlations were tested 1-sided with a p value of 0.05. All other 
tests were performed 2 sided and a significance level of < 0.05 was 
used to reject the null hypothesis. For all calculations, cases in 
which essential data missed were excluded from analysis.
Results
A total of 223 patients treated in both hospitals be-
tween 2010 and 2015 with primary CRS and HIPEC for 
colorectal PC were included. All 68 elegible patients from 
centre B were included and compared with the 68 best 
matching patients from centre A. Table 1 summarizes 
general characteristics. After matching, no significant dif-
ferences could be demonstrated in patient and tumour 
characteristics of patients in both groups. 
Complete cytoreduction (CC0) was achieved in 
95.6% of treated patients. Procedure time was shorter in 
centre A than that in B with 367 and 417 min respec-
tively (p < 0.001). Patients treated in B had a higher es-
timated intraoperative loss of blood volume (p < 0.001); 
this however did not result in a difference in postopera-
tive blood haemoglobin levels. Mitomycin C and oxali-
platin protocols were used in 115 patients (84.6%) and 
21 patients (15.4%) respectively. All patients who were 
treated with oxaliplatin had surgery in centre B. Total 
omentectomy including the gastro-omental arcade was 
performed in 25 patients (18.4%) in centre B. In 23 
(16.9%) centre B patients, the gastro-omental arcade 
was spared and in the remaining 88 patients of (64.7%) 
the arcade status was not unequivocally described. Time 
to removal of nasogastric tube and oral tolerance of food 
was not statistically different in these groups (p = 0.933 
and p = 0.633). 
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Table 1. Characteristics of patients, primary tumours and treatment procedures
Characteristics All patients
(n = 136; 100%)
A
(n = 68; 50%)
B
(n = 68; 50%)
p value
Patient characteristics
Gender, n (%)
Male
Female
Age, years, mean ± SD
BMI, kg/m2, median (range)
ASA 
I–II
III–IV
60 (44.1)
76 (55.9)
61.4±10.7
24.4 (17.9–40.0)
127
9
32 (47.1)
36 (52.9)
61.6±10.1
24.6 (18–36)
66
2
28 (41.2)
40 (58.8)
61.1±11.4
24.3 (18–40)
61
7
0.490
0.749
0.969
0.165
Tumour characteristics
PC presentation
Synchonous
Metachronous
PCI, median (range)
Tumour location
Appendix
Right colon
Transverse
Left colon
Sigmoid
Rectum
Multiple
pT status
≤3
4
x
pN status
N0
N1
N2
Nx
68 (50.0)
68 (50.0)
9.0 (0–24)
3 (2.2)
53 (39.0)
6 (4.4)
9 (6.6)
48 (35.3)
16 (11.8)
1 (0.7)
69 (50.7)
65 (47.8)
2 (1.5)
40 (29.4)
41 (30.1)
51 (37.5)
10 (2.9)
34 (50.0)
34 (50.0)
7.5 (2–21)
0 (0)
23 (33.8)
4 (5.9)
5 (7.4)
27 (39.7)
9 (13.2)
0 (0.0)
37 (54.4)
31 (45.6)
0
22 (32.3)
18 (26.5)
28 (41.2)
0
34 (50.0)
34 (50.0)
10 (0–24)
3 (4.4)
30 (44.1)
2 (2.9)
4 (5.9)
21 30.9)
7 (10.3)
1 (1.5)
32 (47.1)
34 (50.0)
2 (2.9)
18 (26.5)
23 (33.8)
23 (33.8)
4 (5.9)
1.000
0.211
0.349
0.568
0.139
Procedure and treatment
Completeness of cytoreduction
CC0
CC1
Procedure time, min, mean ± SD
Blood loss, mL, median (range)
Postoperative Hb difference
HIPEC
Mitomycin C
Oxaliplatin
Bowel anastomosis
0
1
>1
Unknown
Protective ostomy
Yes
No
Peroperative serosal injury
Peroperative JJ-stent placement 
Days ICU
Hospital stay, days, median (range)
133 (97.8)
3 (2.2)
475±126
1,500 (100–7,500)
–1.3±1.1
115 (84.6)
21 (15.4)
51 (37.5)
65 (47.8)
19 (14.0)
1 (0.7)
8 (5.8)
128 (94.2)
46 (33.8)
15 (11.0)
2 (0–38)
11 (6–84)
66 (97.1)
2 (2.9)
367±69
800 (100–4,200)
–1.5±1.0
67 (98.5)
1 (1.5)
25 (36.8)
33 (48.5)
10 (7.4)
0 (0)
6 (8.8)
62 (91.2)
17 (25)
13 (19.1)
2 (0–38)
12 (7–84)
67 (98.5)
1 (1.5)
417±162
1,993 (150–7,500)
–1.2±1.3
48 (70.6)
20 (29.4)
26 (38.2)
32 (47.0)
9 (13.2)
1 (1.5)
2 (2.9)
66 (97.1)
29 (42.6)
2 (2.9)
2 (1–3)
11 (6–80)
1.000
<0.001
<0.001
0.104
<0.001
0.619
0.162
0.396
0.002
0.471
0.546
PC, peritoneal cancer; PCI, peritoneal cancer index; ICU, intensive care unit.
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Complications
A complicated postoperative course was observed 
in 105 (77.2%) of all patients and 24 (17.6%) had grades 
III–IV Clavien-Dindo complications (Table 2).
Grades III–V were more commonly observed in A: n = 
18 (26.4%) vs. n = 8 (11.8%) in B (p = 0.03). Most com-
mon grades III–IV complications were anastomotic leak-
ages, fistulas and intra-abdominal abscesses.
Infectious complications were more prominent in 
centre A – 29 (42.6%) vs. 13 (19.1%) in B (p = 0.003) – in-
cluding a difference in the incidence of wound-, urinary 
tract-, other infections and the incidence of anastomotic 
leakage. In centre B, fewer urinary tract infections oc-
curred: n = 2 (2.9%) vs. n = 9 (13.2%) in centre A (p = 
0.028). In centre A, 13 (19.1%) patients had a double J 
stent placed preoperatively. Of those patients, 5 (38.5%) 
developed an infection of the urinary tract. The numbers 
for the whole study were 15 and 5, respectively (33%). 
Median hospital stay was not statistically different be-
tween the centres: 12 days (7–84) in A and 11 (6–80) in B 
(p = 0.546).
A higher PCI was related with a longer HS (p = 0.03). 
And a longer HS was moderately correlated with oral in-
tolerance (r = 0.632, p < 0.001). 
Standard TPN and TPN on Demand
TPN was administered per protocol in 98.5% (1 patient 
did not receive TPN due to line failure) of patients in cen-
tre B. In centre A, 54.4% of the patients had an indication 
to administer TPN and were treated accordingly (Table 3). 
The duration of TPN was longer in A with a median of 10 
(4–65) vs. 8 (0–28) days postoperatively in B (p = 0.03). 
Generally, TPN was ended before discharge. The day of 
first oral tolerance and nasogastric tube removal was 1 day 
earlier in A (p = 0.03, p < 0.001), but in A, nasogastric tubes 
were reinserted more frequently: n = 18 vs. n = 7 (p = 
0.018). First stool occurred on day 5 in both groups and 
abdominal wound drains were removed earlier in A with 
median day 3 vs. 7 in B (p < 0.001). 
Discussion
CRS combined with HIPEC is a curative multimo-
dality approach for peritoneal carcinomatosis with a 
relatively high rate of morbidity and delayed return of 
gastrointestinal functions compared to other abdomi-
nal surgical procedures. Postoperative complications 
and gastrointestinal recovery were carefully registered 
in 2 Dutch tertiary referral hospitals for this surgical 
technique. Despite central intravenous catheter-relat-
ed postoperative morbidity, a postoperative protocol 
with standard SDD, TPN and SPCs showed a de-
creased incidence of severe postoperative morbidity. 
The incidence of delayed return of gastrointestinal 
function was remarkably high compared to what is 
described for other gastrointestinal surgical proce-
dures [29–32]. 
Table 2. Complications per hospital
Complications All patients
(n = 136; 100%)
A
(n = 68; 50%)
B
(n = 68; 50%)
p value
Any complication
Uncomplicated
Clavien Dindo score
I
II
III
IV
V
Any infection
Wound
Urinary tract
Line 
Other
Intra-abdominal
Other
105 (77.2)
31 (22.8)
17 (12.5)
62 (45.6)
15 (11.0)
9 (6.6)
2 (1.5)
42 (30.9)
24 (17.6)
11 (8.1)
5 (3.7)
13 (9.6)
20 (14.7)
8 (5.9)
48 (70.6)
20 (29.4)
8 (11.8)
22 (32.4)
10 (14.7)
6 (8.8)
2 (2.9)
29 (42.6)
17 (25.0)
9 (13.2)
N
10 (14.7)
14 (20.6)
1 (1.5)
57 (83.8)
11 (16.2)
9 (13.2)
40 (58.8)
5 (7.4)
3 (4.4)
0 (0.0)
13 (19.1)
7 (10.3)
2 (2.9)
5 (7.4)
3 (4.4)
6 (8.8)
7 (10.3)
0.066
0.028
0.003
0.024
0.028
–
0.041
0.053
0.062
N, not scored or described.
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To minimize selection bias and create a representative 
patient group, all consecutive patients over 5 years from 
one centre were included and matched for all known im-
portant risk factors with patients from the larger cohort 
of the other centre. 
The difference in medication used for the perfusion be-
tween the centres differed between study groups. However, 
available studies comparing the results of mitomycin C with 
oxaliplatin in the setting of HIPEC have shown very similar 
results with respect to postoperative complications [33–
35].
Complications and Infections
The total complication rate was higher in centre B, 
but severe complications were more common in centre 
A. Differences in perioperative care protocols might 
have an effect on the type of complications and compli-
cation rates, but the retrospective nature of this study 
prevents any direct association. There was a substantial 
difference between the centres considering the time ab-
dominal drains were kept, but a recent meta-analysis 
showed that early drain removal after abdominal sur-
gery is neither beneficial nor detrimental when related 
to infection rates [36]. In pelvic surgery, a lower inci-
dence of urinary tract infections was previously de-
scribed with the use of SPCs over transurethral catheters 
[37]. More urinary tract infections were found in centre 
A, where urethral catheters were used as standard of 
care. However, the incidence of double-J stents was also 
higher in this population. J-J stents were placed when 
indicated after distal ureteral reimplantations or recon-
structions. In the total cohort, 45% of patients with a 
urinary tract infection (n = 11) had a double-J stent (n = 
5), suggesting a higher susceptibility for urinary tract 
infections in these patients. The effect of urethral- or su-
prapubic catheters in combination with double-J-stents 
remains unclear because of the limited number of pa-
tients with double J stents.
Gastrointestinal Recovery
Gastrointestinal recovery seems to take more time in 
CRS and HIPEC procedures than in other fields of ab-
dominal surgery [29–32]. Although we observed a rela-
tion between PCI and hospital stay in the total cohort, 
differences in postoperative recovery did not seem to 
correspond with differences in length of postoperative 
stay between the centres. After major abdominal surgi-
cal procedures, patients may experience severe nausea 
and vomiting after oral ingestion of food for several days 
postoperatively. In those cases, patients are at risk of as-
piration, dehydration or malnutrition. Relief of symp-
toms may be achieved by nasogastric tube placement 
and additional TPN for nutritional purposes. Reinser-
tion of nasogastric tubes was more often necessary in 
group A, which could be due to premature removal post-
operatively. 
Enteral nutrition is suggested to be the preferred op-
tion whenever adequately possible, since it is associated 
with fewer (septic) complications, reduced costs, lower 
incidence of ileus or anastomotic leakage and a shorter 
hospital stay [38–41]. Also, a better perioperative nutri-
tional status is associated with less number of complica-
tions in gastro-intestinal surgery patients [42] and the 
patient with peritoneal carcinomatosis is often in sub-
Table 3. Parameters of gastrointestinal status
Gastrointestinal status All patients
(n = 136; 100%)
A
(n = 68; 50%)
B
(n = 68; 50%)
p value
TPN, n (%) 104 (77) 37 (54.4) 67 (98.5) <0.001
TPN start, days 1 (0–23) 3.5 (0–23) 1 (0–3) <0.001
TPN stop, days, median (range) 8.0 (0–65) 10 (4–65) 8 (2–28) 0.043
TPN total, days 7 (1–61) 5 (1–61) 7 (2–20) 0.243
NT stop, days, median (range) 3 (0–71) 3 (0–10) 4 (1–71) 0.002
NT reinsertion, n (%) 25 (18.4) 18 (26.5) 7 (10.3) 0.018
First stool, days, median (range) 5 (1–12) 5 (1–11) 5 (1–12) 0.430
OT, days, median (range) 5 (1–76) 5 (1–17) 6 (2–76) 0.034
AWD stop, days, median (range) 5 (2–20) 3 (2–10) 7 (2–20) <0.001
First stool > day 4, n (%) 68 (50)* 34 (50) 34 (50) 0.924
First OT > day 4, n (%) 76 (55.9)** 32 (47.1) 44 (64.7) 0.019* 9 not described; ** 13 not described.
TPN, total parenteral nutrition; NT, nasogastric tube; OT, oral tolerance; AWD, abdominal wound drains. 
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optimal nutritional status even before surgery. TPN is 
standard of care in centre B, as opposed to the other 
centre where it is used when oral intake of food and 
calories was insufficient after several days. The number 
of days to oral tolerance and nasogastric tube relief was 
smaller in centre A, which might be explained by the 
early enteral feeding policy and a more aggressive poli-
cy in removing nasogastric tubes and enteral feeding. 
The difference in time to oral tolerance, however, did 
not result in a difference in hospital stay. Theoretically 
a better nutritional status resulting from TPN could re-
duce the susceptibility for infections, although this re-
mains unclear. The present study shows that TPN was 
still a necessity in over half of patients to ensure ade-
quate nutrition intake, while an early enteral feeding 
policy is supposed to result in an earlier oral tolerance 
for food. Ideally clinicians should be able to determine 
which specific patients would benefit from different 
feeding policies. However, the exploratory setup of this 
study does not allow a fair comparison of TPN versus 
early enteral feeding.
Conclusions
The current exploratory study provides insight into 
the duration of recovery of the gastrointestinal tract in 
CRS and HIPEC patients. Significantly less severe infec-
tious complications were observed in a group of CRS and 
HIPEC patients treated with a care protocol that involved 
standard TPN, SDD and SPCs. Moreover, TPN was un-
avoidable in a large part of CRS and HIPEC patients with 
an early enteral feeding policy. 
The study shows a significant difference in relevant 
early outcome of the treatment. The differences between 
care protocols might well explain these differences on 
theoretical grounds. The burden of these complications 
for patients and hospital finance demands prospective 
evaluation in a multicentre study.
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